PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

The resurgence of cancer immunotherapy stems from an improved understanding of the tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising data demonstrating a restoration of host immunity against tumors, with the prospect of durable remissions. Indeed, remarkable clinical responses have been seen in several different malignancies including, but not limited ...

PD-L1 expression as a potential predictive biomarker.

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignancies. However, a lot of cancer patients failed to respond to the PD-1/PD-L1 checkpoint blockades. It is crucial to identify a biomar...

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

BACKGROUND Clinical trials of immune checkpoints modulators, including both programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have recently shown promising activity and tolerable toxicity in pre-treated NSCLC patients. However the predictive role of PD-L1 expression is still controversial. This pooled analysis aims to clarify the association of clinical objec...

Circulating Tumor Cells (CTCs) as Biomarker for PD-1/PD-L1 Blockade Immunotherapy

Chunyan YUE1,2 and Zhiyuan HU1,2,3* 1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, P.R. China. 2Sino-Danish College, University of Chinese Academy of Sciences, Beijing 100049, P. R. China 3Yangtze River Delta Academy of Nanotechnology and Industry Devel...